Evidence map›Paper›PMID 31548822›Full record

ArticleCurrent oncology (Toronto, Ont.)2019

Active treatment in low-risk prostate cancer: a population-based study.

S Roy, M E Hyndman, B Danielson, A Fairey, R Lee-Ying, W Y Cheung, A R Afzal, Y Xu, T Abedin, H C Quon

Open access · goldAbstract read
In one paragraph

Article in Current oncology (Toronto, Ont.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

S RoyTom Baker Cancer Centre, Calgary, AB.
M E HyndmanSouthern Alberta Institute of Urology, Calgary, AB.
B DanielsonCross Cancer Institute, Edmonton, AB.
A FaireyDivision of Urology, Department of Surgery, University of Alberta, Edmonton, AB.
R Lee-YingTom Baker Cancer Centre, Calgary, AB.
W Y CheungTom Baker Cancer Centre, Calgary, AB.
A R AfzalTom Baker Cancer Centre, Calgary, AB.
Y XuDepartment of Community Health Sciences, University of Calgary, Calgary, AB.
T AbedinTom Baker Cancer Centre, Calgary, AB.
H C QuonTom Baker Cancer Centre, Calgary, AB.
University of Calgary · CACancer Institute (WIA) · INSAIT Polytechnic · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Active surveillance instead of active treatment (at) is preferred for patients with low-risk prostate cancer (lr-pca), but practice varies widely. We conducted a population-based study to assess the proportion of patients who underwent at between January 2011 and December 2014, and to evaluate factors associated with at. Methods: The provincial cancer registry was linked to administrative health datasets to identify patients with lr-pca and to acquire demographic, tumour, and treatment data. The primary outcome was receipt of at during the first 12 months after diagnosis, defined as any receipt of external-beam radiotherapy, brachytherapy, radical prostatectomy, cryotherapy, or androgen deprivation. Univariate and multivariate logistic regression were used to analyze the correlation between patient and tumour factors and at. Results: Of 1565 patients with lr-pca, 554 (35.4%) underwent at within 12 months of diagnosis. Radical prostatectomy was the most common treatment (58%), followed by brachytherapy (29.6%). Younger age [odds ratio (or) 0.92; 95% confidence interval (ci): 0.91 to 0.94], lower score (≥3) on the Charlson comorbidity index (OR: 0.36; 95% ci: 0.19 to 0.68), T2 stage (or: 3.05; 95% ci: 2.03 to 4.58), higher prostate-specific antigen (psa) at diagnosis (or: 1.13; 95% ci: 1.06 to 1.21), radiation oncologist consultation (or: 3.35; 95% ci: 2.55 to 4.39), and earlier diagnosis year (2012 or: 0.46; 95% ci: 0.34 to 0.63; 2013 or: 0.45; 95% ci: 0.32 to 0.63; 2014 or: 0.33; 95% ci: 0.23 to 0.47) were associated with a higher probability of at. Conclusions: This contemporary population-based study demonstrates that approximately one third of patients with lr-pca undergo at. Patients of younger age, with less comorbidity, a higher tumour stage, higher psa, earlier year of diagnosis, and radiation oncologist consultation were more likely to undergo at. Further investigation is needed to identify strategies that could minimize overtreatment.

Indexed as

AgedAndrogen AntagonistsBrachytherapyCryotherapyHumansLogistic ModelsMaleMiddle AgedNeoplasm GradingOdds RatioProstatectomyProstate-Specific AntigenProstatic NeoplasmsResearch DesignRetrospective StudiesTime-to-TreatmentAndrogen AntagonistsProstate-Specific Antigenactive surveillanceactive treatmentbrachytherapyProstate cancer, low-riskradical prostatectomyradiotherapy

Identifiers

PMID31548822
PMCPMC6726256
OpenAlexW2970365040

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.